Cargando…

Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care

The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multidisciplinary approach is essential to the success...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Angela, Vicenzi, Paige, Sharma, Ishna, Orr, Kaci, Teller, Christa, Koentz, Micha, Trinkman, Heidi, Vallance, Kelly, Ray, Anish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123678/
https://www.ncbi.nlm.nih.gov/pubmed/37092519
http://dx.doi.org/10.3390/hematolrep15020025
_version_ 1785029708862193664
author Liu, Angela
Vicenzi, Paige
Sharma, Ishna
Orr, Kaci
Teller, Christa
Koentz, Micha
Trinkman, Heidi
Vallance, Kelly
Ray, Anish
author_facet Liu, Angela
Vicenzi, Paige
Sharma, Ishna
Orr, Kaci
Teller, Christa
Koentz, Micha
Trinkman, Heidi
Vallance, Kelly
Ray, Anish
author_sort Liu, Angela
collection PubMed
description The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multidisciplinary approach is essential to the success of MTBs. Our MTB, consisting of pediatric oncologists, pathologists, and pharmacists, evaluated 115 cases diagnosed between March 2016 and September 2021. If targetable mutations were identified, pharmacists aided in the evaluation of treatment options based on drug accessibility. Treatable genetic alterations detected through molecular testing most frequently involved the cell cycle. For 85% of the cases evaluated, our MTB provided treatment recommendations based on the patient’s history and results of molecular tumor testing. Only three patients, however, received MTB-recommended targeted therapy, and only one of these patients demonstrated an improved clinical outcome. For the remaining patients, MTB-recommended treatment often was not administered because molecular tumor profiling was not performed until late in the disease course. For the three patients who did receive MTB-recommended therapy, such treatment was not administered until months after diagnosis due to physician preference. Thus, the education of healthcare providers regarding the benefits of targeted therapy may increase acceptance of these novel agents and subsequently improve patient survival.
format Online
Article
Text
id pubmed-10123678
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101236782023-04-25 Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care Liu, Angela Vicenzi, Paige Sharma, Ishna Orr, Kaci Teller, Christa Koentz, Micha Trinkman, Heidi Vallance, Kelly Ray, Anish Hematol Rep Article The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multidisciplinary approach is essential to the success of MTBs. Our MTB, consisting of pediatric oncologists, pathologists, and pharmacists, evaluated 115 cases diagnosed between March 2016 and September 2021. If targetable mutations were identified, pharmacists aided in the evaluation of treatment options based on drug accessibility. Treatable genetic alterations detected through molecular testing most frequently involved the cell cycle. For 85% of the cases evaluated, our MTB provided treatment recommendations based on the patient’s history and results of molecular tumor testing. Only three patients, however, received MTB-recommended targeted therapy, and only one of these patients demonstrated an improved clinical outcome. For the remaining patients, MTB-recommended treatment often was not administered because molecular tumor profiling was not performed until late in the disease course. For the three patients who did receive MTB-recommended therapy, such treatment was not administered until months after diagnosis due to physician preference. Thus, the education of healthcare providers regarding the benefits of targeted therapy may increase acceptance of these novel agents and subsequently improve patient survival. MDPI 2023-04-04 /pmc/articles/PMC10123678/ /pubmed/37092519 http://dx.doi.org/10.3390/hematolrep15020025 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Angela
Vicenzi, Paige
Sharma, Ishna
Orr, Kaci
Teller, Christa
Koentz, Micha
Trinkman, Heidi
Vallance, Kelly
Ray, Anish
Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
title Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
title_full Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
title_fullStr Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
title_full_unstemmed Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
title_short Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
title_sort molecular tumor boards: the next step towards precision therapy in cancer care
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123678/
https://www.ncbi.nlm.nih.gov/pubmed/37092519
http://dx.doi.org/10.3390/hematolrep15020025
work_keys_str_mv AT liuangela moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT vicenzipaige moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT sharmaishna moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT orrkaci moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT tellerchrista moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT koentzmicha moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT trinkmanheidi moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT vallancekelly moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare
AT rayanish moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare